FDA Approves ZYPREXA INTRAMUSCULAR — Eli Lilly and Company

# FDA Approves Eli Lilly's ZYPREXA Intramuscular Formulation Eli Lilly and Company received FDA approval for ZYPREXA (olanzapine) intramuscular injection, expanding its antipsychotic portfolio beyond oral formulations and positioning the company to capture additional market share in the acute psychiatric care segment. The new injectable route is expected to enhance treatment compliance and open new revenue opportunities in hospital and emergency care settings where parenteral administration is preferred.